Overall, the newer small molecule GLP-1 RAs such as danuglipron and orforglipron have shown significant reductions in HbA1c and body weight, comparable to existing GLP-1 RAs
Common side effects from Phase 2 data include nausea, vomiting, diarrhoea, and constipation, consistent with the GLP-1 receptor agonist drug class
May 28, 2024
Section 503A pharmacies faced an earlier deadline to cease compounding, followed by 503B facilities
Mounjaro (tirzepatide) works by activating two hormones involved in appetite and blood sugar regulation: Retatrutide works on three hormones, which is why it is often referred to as a triple-agonist. It activates: The addition of glucagon is what makes retatrutide different
Retatrutide may appeal to individuals seeking: Significant weight reduction Advanced obesity treatment options Enhanced appetite control Comprehensive metabolic support Its triple-receptor mechanism has made it one of the most closely watched developments in obesity medicine